succinobucol

(redirected from AGI-1067)

succinobucol

An antioxidant and anti-inflammatory compound belonging to a new class of agents—composite vascular protectants—which also has potential as an anti-diabetic agent.

Mechanism
Succinobucol blocks production of certain inflammatory mediators (e.g., VCAM-1 and MCP-1), which are implicated in atherosclerosis. Succinobucol may reduce or reverse morbidity and mortality of coronary heart disease, as well as the rate of restenosis in stents.
References in periodicals archive ?
AtheroGenics, which has been testing a drug called AGI-1067 against diabetes after it failed for heart disease, said Sept.
With the recent setbacks reported with other HDL modulators like torcetrapib and AGI-1067, Apo AI is clearly positioned at the forefront of cardiovascular disease therapy (see Nature 2006 Dec 14; pages 794-5).
Shares in drugs giant AstraZeneca look set for a bumpy ride in the next fortnight, with positive news expected for cholesterol fighter Cres-tor but experimental heart drug AGI-1067 widely tipped to fail in a key study.
on the signing of a significant commercialization agreement for AGI-1067, its novel oral therapy for the treatment of atherosclerosis.
The company currently has 4 vascular protectant programs in development including AGI-1067, an oral agent in Phase II clinical trials for the treatment of retenosis and atherosclerosis.
06, The tiny drug developer is working on a medicine for treating coronary heart disease, and investors are waiting on news about the latest clinical trial of compound AGI-1067.
Biosimilar Epogen, Avastin, Acomplia, and AstraZeneca/AtheroGenics' AGI-1067 Will All Have a Good Year, According to Decision Resources' 'Top Ten Pharma Predictions for 2007'
From the same AGIX report: "The company previously released phase III data on lead compound AGI-1067 that did not meet the primary end point.
AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis in collaboration with AstraZeneca.
6% for the highest (150mg) dose, and continued signs of elevate liver activity give us cause to remain skeptical of the eventual commercial potential of AGI-1067.
The 08 Noteholders believe that the proposal would have permitted AtheroGenics to meet its payment obligations under the 08 Notes and to meet other short- and long-term goals, including completion of the development of AGI-1067 through its second, confirmatory Phase 3 trial, and to avoid defaults of AtheroGenics' other outstanding debt.
The increase in both periods versus the prior year resulted from clinical trial expenditures associated with the Company's AGI-1067 development program, including the ongoing ARISE Phase III clinical study in atherosclerosis, and associated costs for additional development personnel.